HLA-G 14 bp In/Del and +3142 C/G genotypes are differentially expressed between patients with grade IV gliomas and controls
Carregando...
Data
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Federal de Minas Gerais
Descrição
Tipo
Artigo de periódico
Título alternativo
Primeiro orientador
Membros da banca
Resumo
Aim: Human Leukocyte Antigen-G (HLA-G) is a non-classical class I molecule that is involved in maternal–fetal immunotolerance. In cancer, this molecule contributes to the tumor escape. The aim of this study was to evaluate the 14 bp In/Del and þ3142 C > G polymorphisms of the HLAG 30 UTR and its relation with plasma and tissue HLA-G expression in patients with grade IV
(high-grade) and grade I/II (low-grade) gliomas and controls. Patients and methods: Peripheral blood and tumor biopsies were collected from 85 patients with gliomas and blood samples from 94 controls. Polymorphisms were analyzed from blood
DNA. Soluble HLA-G (sHLA-G) was measured by ELISA in plasma of the subjects and the tissue expression by immunohistochemistry on patient’s tissue. Results: Higher levels of sHLA-G were observed in grade IV gliomas patients than in controls (p < 0.0001). In grade IV patients, the heterozygous 14pb In/Del, þ3142 C/G genotypes and Del/C In/G haplotype were associated with higher sHLA-G levels (p < 0.0001) when compared with controls. GBM patients were stratified into high and low sHLA-G expression and an association
was found between þ3142 C allele and high sHLA-G plasmatic levels (p ¼ 0.0095). Tissue HLA-G immunolabel was higher in high-grade than low-grade gliomas (p ¼ 0.0033). Conclusion: This was the first study evaluating HLA-G 30 UTR polymorphisms and expression in patients with gliomas. The 14 bp In/Del and þ3142 C/G genotypes and haplotypes showed high influence over sHLA-G expression, suggesting a heterozygous advantage in the tumor context and may contribute to a worse prognosis in glioma patients.
Abstract
Assunto
Neoplasias Encefálicas, Glioma
Palavras-chave
Brain tumors, GBM, HLA-G polymorphism, 3' UTR;, Plasma expression
Citação
Curso
Endereço externo
https://www.tandfonline.com/doi/full/10.1080/00207454.2020.1744593